Insights into real-world data in advanced HCC
Insights into real-world data in advanced HCC
Video update and slides
Video update and slides
Assoc. Prof. Matthias Pinter
In this video update, HCC CONNECT expert Prof. Matthias Pinter reviews recent real-world data (RWD) discussed in advanced HCC.
He discusses real-world efficacy and safety of systemic therapies, treatment patterns in real-world clinical practice, and RWD on systemic therapy in patient populations excluded from Phase 3 RCT (Child-Pugh class B and with a history of liver transplantation).
Clinical takeaways:
- Although RWD cannot substitute controlled randomised clinical trials, RWD addresses questions not sufficiently answered by clinical trial data
- RWD can provide insights into the performance and outcomes of new anticancer therapies in routine clinical practice, information on patients underrepresented in clinical trials and captures less common and delayed adverse events
Assoc. Prof. Matthias Pinter
Hepatologist
Medical University of Vienna
Austria
Real-world data in advanced HCC
| 
6 min
|
Dec 2022
download resources
I agree that this educational programme:
This educational programme is supported by an Independent Medical Education Grant from Bayer
HCC CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Bayer, AstraZeneca and from Eisai Europe Limited.
Other programmes of interest
60 min
Other programmes developed by Assoc. Prof. Matthias Pinter
Assoc. Prof. Matthias Pinter
Hepatologist
Medical University of Vienna
Austria
